1
|
Martin-Blazquez A, Martin-Lorenzo M, Santiago-Hernandez A, Heredero A, Donado A, Lopez JA, Anfaiha-Sanchez M, Ruiz-Jimenez R, Esteban V, Vazquez J, Aldamiz-Echevarria G, Alvarez-Llamas G. Analysis of Vascular Smooth Muscle Cells from Thoracic Aortic Aneurysms Reveals DNA Damage and Cell Cycle Arrest as Hallmarks in Bicuspid Aortic Valve Patients. J Proteome Res 2024; 23:3012-3024. [PMID: 38594816 PMCID: PMC11301675 DOI: 10.1021/acs.jproteome.3c00649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 02/26/2024] [Accepted: 03/24/2024] [Indexed: 04/11/2024]
Abstract
Thoracic aortic aneurysm (TAA) is mainly sporadic and with higher incidence in the presence of a bicuspid aortic valve (BAV) for unknown reasons. The lack of drug therapy to delay TAA progression lies in the limited knowledge of pathophysiology. We aimed to identify the molecular hallmarks that differentiate the aortic dilatation associated with BAV and tricuspid aortic valve (TAV). Aortic vascular smooth muscle cells (VSMCs) isolated from sporadic TAA patients with BAV or TAV were analyzed by mass spectrometry. DNA oxidative damage assay and cell cycle profiling were performed in three independent cohorts supporting proteomics data. The alteration of secreted proteins was confirmed in plasma. Stress phenotype, oxidative stress, and enhanced DNA damage response (increased S-phase arrest and apoptosis) were found in BAV-TAA patients. The increased levels of plasma C1QTNF5, LAMA2, THSB3, and FAP confirm the enhanced stress in BAV-TAA. Plasma FAP and BGN point to an increased inflammatory condition in TAV. The arterial wall of BAV patients shows a limited capacity to counteract drivers of sporadic TAA. The molecular pathways identified support the need of differential molecular diagnosis and therapeutic approaches for BAV and TAV patients, showing specific markers in plasma which may serve to monitor therapy efficacy.
Collapse
Affiliation(s)
- Ariadna Martin-Blazquez
- Immunology
Department, IIS-Fundación Jiménez
Díaz, Fundación Jiménez Díaz Hospital-UAM, 28040 Madrid, Spain
| | - Marta Martin-Lorenzo
- Immunology
Department, IIS-Fundación Jiménez
Díaz, Fundación Jiménez Díaz Hospital-UAM, 28040 Madrid, Spain
| | | | - Angeles Heredero
- Cardiac
Surgery Service, Fundación Jiménez
Díaz Hospital-UAM, 28040 Madrid, Spain
| | - Alicia Donado
- Cardiac
Surgery Service, Fundación Jiménez
Díaz Hospital-UAM, 28040 Madrid, Spain
| | - Juan A Lopez
- Laboratory
of Cardiovascular Proteomics, Centro Nacional
de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
- CIBER
de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
| | - Miriam Anfaiha-Sanchez
- Immunology
Department, IIS-Fundación Jiménez
Díaz, Fundación Jiménez Díaz Hospital-UAM, 28040 Madrid, Spain
| | - Rocio Ruiz-Jimenez
- Immunology
Department, IIS-Fundación Jiménez
Díaz, Fundación Jiménez Díaz Hospital-UAM, 28040 Madrid, Spain
| | - Vanesa Esteban
- Department
of Allergy and Immunology, IIS-Fundación
Jiménez Díaz, Fundación Jiménez Díaz
Hospital-UAM, 28040 Madrid, Spain
- Faculty
of Medicine and Biomedicine, Alfonso X El
Sabio University, 28691 Madrid, Spain
| | - Jesus Vazquez
- Laboratory
of Cardiovascular Proteomics, Centro Nacional
de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
- CIBER
de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
| | | | - Gloria Alvarez-Llamas
- Immunology
Department, IIS-Fundación Jiménez
Díaz, Fundación Jiménez Díaz Hospital-UAM, 28040 Madrid, Spain
- RICORS2040, Fundación Jiménez Díaz, 28040 Madrid, Spain
- Department
of Biochemistry and Molecular Biology, Complutense
University, 28040 Madrid, Spain
| |
Collapse
|
2
|
Wang Z, Wang J, Lan T, Zhang L, Yan Z, Zhang N, Xu Y, Tao Q. Role and mechanism of fibroblast-activated protein-α expression on the surface of fibroblast-like synoviocytes in rheumatoid arthritis. Front Immunol 2023; 14:1135384. [PMID: 37006278 PMCID: PMC10064071 DOI: 10.3389/fimmu.2023.1135384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Accepted: 03/07/2023] [Indexed: 03/19/2023] Open
Abstract
Fibroblast-activated protein-α (FAP) is a type II integrated serine protease expressed by activated fibroblasts during fibrosis or inflammation. Fibroblast-like synoviocytes (FLSs) in rheumatoid arthritis (RA) synovial sites abundantly and stably overexpress FAP and play important roles in regulating the cellular immune, inflammatory, invasion, migration, proliferation, and angiogenesis responses in the synovial region. Overexpression of FAP is regulated by the initial inflammatory microenvironment of the disease and epigenetic signaling, which promotes RA development by regulating FLSs or affecting the signaling cross-linking FLSs with other cells at the local synovium and inflammatory stimulation. At present, several treatment options targeting FAP are in the process of development. This review discusses the basic features of FAP expressed on the surface of FLSs and its role in RA pathophysiology and advances in targeted therapies.
Collapse
Affiliation(s)
- Zihan Wang
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
- Graduate school, Beijing University of Chinese Medicine, Beijing, China
| | - Jinping Wang
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
| | - Tianyi Lan
- Graduate school, Beijing University of Chinese Medicine, Beijing, China
| | - Liubo Zhang
- Graduate school, Beijing University of Chinese Medicine, Beijing, China
| | - Zeran Yan
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
| | - Nan Zhang
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
| | - Yuan Xu
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
- *Correspondence: Yuan Xu, ; Qingwen Tao,
| | - Qingwen Tao
- Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital, Beijing, China
- *Correspondence: Yuan Xu, ; Qingwen Tao,
| |
Collapse
|
3
|
Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Regulation of Fibroblast Activation Protein-α Expression: Focus on Intracellular Protein Interactions. J Med Chem 2021; 64:14028-14045. [PMID: 34523930 DOI: 10.1021/acs.jmedchem.1c01010] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The prolyl-specific peptidase fibroblast activation protein-α (FAP-α) is expressed at very low or undetectable levels in nondiseased human tissues but is selectively induced in activated (myo)fibroblasts at sites of tissue remodeling in fibrogenic processes. In normal regenerative processes involving transient fibrosis FAP-α+(myo)fibroblasts disappear from injured tissues, replaced by cells with a normal FAP-α- phenotype. In chronic uncontrolled pathological fibrosis FAP-α+(myo)fibroblasts permanently replace normal tissues. The mechanisms of regulation and elimination of FAP-α expression in(myo)fibroblasts are unknown. According to a yeast two-hybrid screen and protein databanks search, we propose that the intracellular (co)-chaperone BAG6/BAT3 can interact with FAP-α, mediated by the BAG6/BAT3 Pro-rich domain, inducing proteosomal degradation of FAP-α protein under tissue homeostasis. In this Perspective, we discuss our findings in the context of current knowledge on the regulation of FAP-α expression and comment potential therapeutic strategies for uncontrolled fibrosis, including small molecule degraders (PROTACs)-modified FAP-α targeted inhibitors.
Collapse
Affiliation(s)
- Lucienne Juillerat-Jeanneret
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland.,University Institute of Pathology, CHUV and UNIL, CH1011 Lausanne, Switzerland
| | - Petra Tafelmeyer
- Hybrigenics Services, Laboratories and Headquarters-Paris, 1 rue Pierre Fontaine, 91000 Evry, France.,Hybrigenics Corporation, Cambridge Innovation Center, 50 Milk Street, Cambridge, Massachusetts 02142, United States
| | - Dela Golshayan
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland
| |
Collapse
|
4
|
Xi CR, Di Fazio A, Nadvi NA, Xiang MSW, Zhang HE, Deshpande C, Chen Y, Tabar MS, Wang XM, Bailey CG, McCaughan GW, Church WB, Gorrell MD. An improved production and purification protocol for recombinant soluble human fibroblast activation protein alpha. Protein Expr Purif 2021; 181:105833. [PMID: 33524496 DOI: 10.1016/j.pep.2021.105833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Revised: 01/22/2021] [Accepted: 01/25/2021] [Indexed: 10/22/2022]
Abstract
Fibroblast activation protein alpha (FAP) is a cell-surface expressed type II glycoprotein that has a unique proteolytic activity. FAP has active soluble forms that retain the extracellular portion but lack the transmembrane domain and cytoplasmic tail. FAP expression is normally very low in adult tissue but is highly expressed by activated fibroblasts in sites of tissue remodelling. Thus, FAP is a potential biomarker and pharmacological target in liver fibrosis, atherosclerosis, cardiac fibrosis, arthritis and cancer. Understanding the biological significance of FAP by investigating protein structure, interactions and activities requires reliable methods for the production and purification of abundant pure and stable protein. We describe an improved production and purification protocol for His6-tagged recombinant soluble human FAP. A modified baculovirus expression construct was generated using the pFastBac1 vector and the gp67 secretion signal to produce abundant active soluble recombinant human FAP (residues 27-760) in insect cells. The FAP purification protocol employed ammonium sulphate precipitation, ion exchange chromatography, immobilised metal affinity chromatography and ultrafiltration. High purity was achieved, as judged by gel electrophoresis and specific activity. The purified 82 kDa FAP protein was specifically inhibited by a FAP selective inhibitor, ARI-3099, and was inhibited by zinc with an IC50 of 25 μM. Our approach could be adopted for producing the soluble portions of other type II transmembrane glycoproteins to study their structure and function.
Collapse
Affiliation(s)
- Cecy R Xi
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Arianna Di Fazio
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Naveed Ahmed Nadvi
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia; Research Portfolio Core Research Facilities, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Michelle Sui Wen Xiang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Hui Emma Zhang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Chandrika Deshpande
- Faculty of Science, School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales, 2006, UK; Drug Discovery, Sydney Analytical, Core Research Facilities, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Yiqian Chen
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Mehdi Sharifi Tabar
- Gene & Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Xin Maggie Wang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Charles G Bailey
- Gene & Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Geoffrey W McCaughan
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia; AW Morrow GE & Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia
| | - W Bret Church
- Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Mark D Gorrell
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, 2006, Australia.
| |
Collapse
|
5
|
Xi CR, Di Fazio A, Nadvi NA, Patel K, Xiang MSW, Zhang HE, Deshpande C, Low JKK, Wang XT, Chen Y, McMillan CLD, Isaacs A, Osborne B, Vieira de Ribeiro AJ, McCaughan GW, Mackay JP, Church WB, Gorrell MD. A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. Molecules 2020; 25:molecules25225392. [PMID: 33218025 PMCID: PMC7698748 DOI: 10.3390/molecules25225392] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 11/09/2020] [Accepted: 11/13/2020] [Indexed: 01/09/2023] Open
Abstract
Proteases catalyse irreversible posttranslational modifications that often alter a biological function of the substrate. The protease dipeptidyl peptidase 4 (DPP4) is a pharmacological target in type 2 diabetes therapy primarily because it inactivates glucagon-like protein-1. DPP4 also has roles in steatosis, insulin resistance, cancers and inflammatory and fibrotic diseases. In addition, DPP4 binds to the spike protein of the MERS virus, causing it to be the human cell surface receptor for that virus. DPP4 has been identified as a potential binding target of SARS-CoV-2 spike protein, so this question requires experimental investigation. Understanding protein structure and function requires reliable protocols for production and purification. We developed such strategies for baculovirus generated soluble recombinant human DPP4 (residues 29–766) produced in insect cells. Purification used differential ammonium sulphate precipitation, hydrophobic interaction chromatography, dye affinity chromatography in series with immobilised metal affinity chromatography, and ion-exchange chromatography. The binding affinities of DPP4 to the SARS-CoV-2 full-length spike protein and its receptor-binding domain (RBD) were measured using surface plasmon resonance and ELISA. This optimised DPP4 purification procedure yielded 1 to 1.8 mg of pure fully active soluble DPP4 protein per litre of insect cell culture with specific activity >30 U/mg, indicative of high purity. No specific binding between DPP4 and CoV-2 spike protein was detected by surface plasmon resonance or ELISA. In summary, a procedure for high purity high yield soluble human DPP4 was achieved and used to show that, unlike MERS, SARS-CoV-2 does not bind human DPP4.
Collapse
Affiliation(s)
- Cecy R Xi
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Arianna Di Fazio
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Naveed Ahmed Nadvi
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
- Research Portfolio Core Research Facilities, The University of Sydney, Sydney, NSW 2006, Australia
| | - Karishma Patel
- Faculty of Science, School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia; (K.P.); (C.D.); (J.K.K.L.)
| | - Michelle Sui Wen Xiang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Hui Emma Zhang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Chandrika Deshpande
- Faculty of Science, School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia; (K.P.); (C.D.); (J.K.K.L.)
- Drug Discovery, Sydney Analytical, Core Research Facilities, The University of Sydney, Sydney, NSW 2006, Australia;
| | - Jason K K Low
- Faculty of Science, School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW 2006, Australia; (K.P.); (C.D.); (J.K.K.L.)
| | - Xiaonan Trixie Wang
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Yiqian Chen
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Christopher L D McMillan
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia; (C.L.D.M.); (A.I.)
| | - Ariel Isaacs
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia; (C.L.D.M.); (A.I.)
| | - Brenna Osborne
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Ana Júlia Vieira de Ribeiro
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
| | - Geoffrey W McCaughan
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
- AW Morrow GE & Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
| | - Joel P Mackay
- Drug Discovery, Sydney Analytical, Core Research Facilities, The University of Sydney, Sydney, NSW 2006, Australia;
| | - W Bret Church
- Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia;
| | - Mark D Gorrell
- Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; (C.R.X.); (A.D.F.); (N.A.N.); (M.S.W.X.); (H.E.Z.); (X.T.W.); (Y.C.); (B.O.); (A.J.V.d.R.); (G.W.M.)
- Correspondence: ; Tel.: +61-2-9565-6156; Fax: +61-2-9565-6101
| |
Collapse
|
6
|
Golyan FF, Moghaddassian M, Forghanifard MM, Talebi S, Farshchian M, Mahmoudian RA, Abbaszadegan MR. Whole Exome Sequencing Reveals a Novel Damaging Mutation in Human Fibroblast Activation Protein in a Family with Esophageal Squamous Cell Carcinoma. J Gastrointest Cancer 2019; 51:179-188. [DOI: 10.1007/s12029-019-00224-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Zhang HE, Hamson EJ, Koczorowska MM, Tholen S, Chowdhury S, Bailey CG, Lay AJ, Twigg SM, Lee Q, Roediger B, Biniossek ML, O'Rourke MB, McCaughan GW, Keane FM, Schilling O, Gorrell MD. Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. Mol Cell Proteomics 2019; 18:65-85. [PMID: 30257879 PMCID: PMC6317473 DOI: 10.1074/mcp.ra118.001046] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Indexed: 01/10/2023] Open
Abstract
Fibroblast activation protein-alpha (FAP) is a cell-surface transmembrane-anchored dimeric protease. This unique, constitutively active serine protease has both dipeptidyl aminopeptidase and endopeptidase activities and can hydrolyze the post-proline bond. FAP expression is very low in adult organs but is upregulated by activated fibroblasts in sites of tissue remodeling, including fibrosis, atherosclerosis, arthritis and tumors. To identify the endogenous substrates of FAP, we immortalized primary mouse embryonic fibroblasts (MEFs) from FAP gene knockout embryos and then stably transduced them to express either enzymatically active or inactive FAP. The MEF secretomes were then analyzed using degradomic and proteomic techniques. Terminal amine isotopic labeling of substrates (TAILS)-based degradomics identified cleavage sites in collagens, many other extracellular matrix (ECM) and associated proteins, and lysyl oxidase-like-1, CXCL-5, CSF-1, and C1qT6, that were confirmed in vitro In addition, differential metabolic labeling coupled with quantitative proteomic analysis also implicated FAP in ECM-cell interactions, as well as with coagulation, metabolism and wound healing associated proteins. Plasma from FAP-deficient mice exhibited slower than wild-type clotting times. This study provides a significant expansion of the substrate repertoire of FAP and provides insight into the physiological and potential pathological roles of this enigmatic protease.
Collapse
Affiliation(s)
- Hui Emma Zhang
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Elizabeth J Hamson
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | | | - Stefan Tholen
- ¶Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany
| | - Sumaiya Chowdhury
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Charles G Bailey
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Angelina J Lay
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Stephen M Twigg
- §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia;; ‖Charles Perkins Centre, the University of Sydney, New South Wales, 2006, Australia
| | - Quintin Lee
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Ben Roediger
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Martin L Biniossek
- ¶Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany
| | - Matthew B O'Rourke
- ‖Charles Perkins Centre, the University of Sydney, New South Wales, 2006, Australia;; **Proteomics Core Facility, University of Technology Sydney, New South Wales, 2007, Australia
| | - Geoffrey W McCaughan
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Fiona M Keane
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia
| | - Oliver Schilling
- ‡‡Institute of Surgical Pathology, University Medical Center - University of Freiburg, Freiburg, Germany;; §§BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany;; ¶¶German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
| | - Mark D Gorrell
- From the ‡Centenary Institute, the University of Sydney, Locked Bag No.6, Newtown, New South Wales, 2042, Australia;; §Sydney Medical School, the University of Sydney Faculty of Medicine and Health, New South Wales, 2006, Australia;; ‖Charles Perkins Centre, the University of Sydney, New South Wales, 2006, Australia;.
| |
Collapse
|
8
|
Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene 2018; 37:4343-4357. [PMID: 29720723 PMCID: PMC6092565 DOI: 10.1038/s41388-018-0275-3] [Citation(s) in RCA: 214] [Impact Index Per Article: 35.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 01/23/2018] [Accepted: 01/29/2018] [Indexed: 02/06/2023]
Abstract
Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma. It has also been proposed as a molecular target of cancer therapies, and, especially in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments. Yet despite this growing field of research, our knowledge of FAP's basic biology and functional roles in various cancers has lagged behind its use as a tumor-stromal marker. In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target. We highlight outstanding questions in the field, the answers to which could shape preclinical and clinical studies of FAP.
Collapse
Affiliation(s)
- Ellen Puré
- University of Pennsylvania, Philadelphia, PA, USA.
| | | |
Collapse
|
9
|
Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Expert Opin Ther Targets 2017; 21:977-991. [DOI: 10.1080/14728222.2017.1370455] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Lucienne Juillerat-Jeanneret
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
- CHUV and UNIL, University Institute of Pathology, Lausanne, Switzerland
| | - Petra Tafelmeyer
- Hybrigenics Services, Laboratories and Headquarters, Paris, France
- Hybrigenics Corporation, Cambridge Innovation Center, Cambridge, MA, USA
| | - Dela Golshayan
- Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
| |
Collapse
|
10
|
Uitte de Willige S, Keane FM, Bowen DG, Malfliet JJMC, Zhang HE, Maneck B, McCaughan GW, Leebeek FWG, Rijken DC, Gorrell MD. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS One 2017; 12:e0178987. [PMID: 28582421 PMCID: PMC5459491 DOI: 10.1371/journal.pone.0178987] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 05/22/2017] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND AND AIM Circulating fibroblast activation protein (cFAP) is a constitutively active enzyme expressed by activated fibroblasts that has both dipeptidyl peptidase and endopeptidase activities. We aimed to assess the correlation between cFAP activity and antigen levels and to compare variations in levels. METHODS In plasma of 465 control individuals, 368 patients with coronary heart disease (CHD) and 102 hepatitis C virus (HCV) infected patients with severe liver disease before and after liver transplant, cFAP activity levels were measured with a newly developed cFAP activity assay. In the same samples, cFAP antigen levels were measured using a commercially available cFAP ELISA. Correlation analyses between activity and antigen levels were performed by calculating Pearson's correlation coefficient (ρ). Additionally, normal ranges, determinants and differences between cohorts and between anticoagulants were investigated. RESULTS cFAP activity and antigen levels significantly correlated in controls (ρ: 0.660, p<0.001) and in CHD patients (ρ: 0.709, p<0.001). cFAP activity and antigen levels in the HCV cohort were significantly lower in the samples taken after liver transplantation (p<0.001) and normalized toward levels of healthy individuals. Furthermore, cFAP activity and antigen levels were higher in men and significantly associated with body mass index. Also, cFAP activity and antigen levels were higher in EDTA plasma as compared to the levels in citrated plasma from the same healthy individuals. CONCLUSIONS For analyzing cFAP levels, either activity levels or antigen levels can be measured to investigate differences between individuals. However, it is of importance that blood samples are collected in the same anticoagulant.
Collapse
Affiliation(s)
- Shirley Uitte de Willige
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
- * E-mail:
| | - Fiona M. Keane
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - David G. Bowen
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | | | - H. Emma Zhang
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Bharvi Maneck
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Geoffrey W. McCaughan
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Frank W. G. Leebeek
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Dingeman C. Rijken
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Mark D. Gorrell
- Department of Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
11
|
Tan SY, Chowdhury S, Polak N, Gorrell MD, Weninger W. Fibroblast activation protein is dispensable in the anti-influenza immune response in mice. PLoS One 2017; 12:e0171194. [PMID: 28158223 PMCID: PMC5291439 DOI: 10.1371/journal.pone.0171194] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 01/18/2017] [Indexed: 01/10/2023] Open
Abstract
Fibroblast activation protein alpha (FAP) is a unique dual peptidase of the S9B serine protease family, being capable of both dipeptidyl peptidase and endopeptidase activities. FAP is expressed at low level in healthy adult organs including the pancreas, cervix, uterus, submaxillary gland and the skin, and highly upregulated in embryogenesis, chronic inflammation and tissue remodelling. It is also expressed by cancer-associated stromal fibroblasts in more than 90% of epithelial tumours. FAP has enzymatic and non-enzymatic functions in the growth, immunosuppression, invasion and cell signalling of tumour cells. FAP deficient mice are fertile and viable with no gross abnormality, but little data exist on the role of FAP in the immune system. FAP is upregulated in association with microbial stimulation and chronic inflammation, but its function in infection remains unknown. We showed that major populations of immune cells including CD4+ and CD8+ T cells, B cells, dendritic cells and neutrophils are generated and maintained normally in FAP knockout mice. Upon intranasal challenge with influenza virus, FAP mRNA was increased in the lungs and lung-draining lymph nodes. Nonetheless, FAP deficient mice showed similar pathologic kinetics to wildtype controls, and were capable of supporting normal anti-influenza T and B cell responses. There was no evidence of compensatory upregulation of other DPP4 family members in influenza-infected FAP-deficient mice. FAP appears to be dispensable in anti-influenza adaptive immunity.
Collapse
Affiliation(s)
- Sioh-Yang Tan
- Immune Imaging Program, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
- Sydney Medical School, The University of Sydney, New South Wales, Australia
| | - Sumaiya Chowdhury
- Sydney Medical School, The University of Sydney, New South Wales, Australia
- Molecular Hepatology Laboratory, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
| | - Natasa Polak
- Sydney Medical School, The University of Sydney, New South Wales, Australia
- Molecular Hepatology Laboratory, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
| | - Mark D. Gorrell
- Sydney Medical School, The University of Sydney, New South Wales, Australia
- Molecular Hepatology Laboratory, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
| | - Wolfgang Weninger
- Immune Imaging Program, Centenary Institute for Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
- Sydney Medical School, The University of Sydney, New South Wales, Australia
- Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| |
Collapse
|
12
|
Wonganu B, Berger BW. A specific, transmembrane interface regulates fibroblast activation protein (FAP) homodimerization, trafficking and exopeptidase activity. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2016; 1858:1876-82. [PMID: 27155568 DOI: 10.1016/j.bbamem.2016.05.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Revised: 04/08/2016] [Accepted: 05/03/2016] [Indexed: 11/29/2022]
Abstract
Fibroblast activation protein (FAP) is a cell-surface serine protease which promotes invasiveness of certain epithelial cancers and is therefore a potential target for cancer drug development and delivery. Unlike dipeptidyl peptidase IV (DPPIV), FAP exhibits prolyl endopeptidase activity and is active as a homodimer with specificity for type I collagen. The mechanism that regulates FAP homodimerization and its relation to prolyl endopeptidase activity is not completely understood. Here, we investigate key residues in the FAP TM domain that may be significant for FAP homodimerization. Mutations to predicted TM interfacial residues (G10L, S14L, and A18L) comprising a small-X3-small motif reduced FAP TM-CYTO dimerization relative to wild type as measured using the AraTM assay, whereas predicted off-interface residues showed no significant change from wild type. The results implied that the predicted small-X3-small dimer interface affect stabilization of FAP TM-CYTO homodimerization. Compared with FAPwild-type, the interfacial TM residue G10L significantly decreased FAP endopeptidase activity more than 25%, and also reduced cell-surface versus intracellular expression relative to other interfacial residues S14L and A18L. Thus, our results suggest FAP dimerization is important for both trafficking and protease activity, and is dependent on a specific TM interface.
Collapse
Affiliation(s)
- Benjamaporn Wonganu
- Program in Bioengineering, Lehigh University, Bethlehem, PA 18015, United States
| | - Bryan W Berger
- Program in Bioengineering, Lehigh University, Bethlehem, PA 18015, United States; Department of Chemical and Biomolecular Engineering, Lehigh University, Bethlehem, PA 18015, United States.
| |
Collapse
|
13
|
Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, Corpuz R, Wong M, Zhou W, Deshmukh G, Ly J, Sutherlin DP, Ernst JA, Sonoda J. Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21. J Biol Chem 2016; 291:5986-5996. [PMID: 26797127 DOI: 10.1074/jbc.m115.710582] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Indexed: 12/16/2022] Open
Abstract
FGF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties. Although proteolytic cleavage of recombinant human FGF21 in preclinical species has been observed previously, the regulation of endogenously produced FGF21 is not well understood. Here we identify fibroblast activation protein (FAP) as the enzyme that cleaves and inactivates human FGF21. A selective chemical inhibitor, immunodepletion, or genetic deletion of Fap stabilized recombinant human FGF21 in serum. In addition, administration of a selective FAP inhibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys. On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alcoholic steatohepatitis, and related metabolic disorders.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Justin Ly
- Drug Metabolism and Pharmacokinetics, and
| | - Daniel P Sutherlin
- Discovery Chemistry, Genentech, Inc., South San Francisco, California 94080
| | | | | |
Collapse
|
14
|
Wong PF, Gall MG, Bachovchin WW, McCaughan GW, Keane FM, Gorrell MD. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. Peptides 2016; 75:80-95. [PMID: 26621486 DOI: 10.1016/j.peptides.2015.11.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Revised: 10/17/2015] [Accepted: 11/20/2015] [Indexed: 12/27/2022]
Abstract
Fibroblast activation protein (FAP) is a dipeptidyl peptidase (DPP) and endopeptidase that is weakly expressed in normal adult human tissues but is greatly up-regulated in activated mesenchymal cells of tumors and chronically injured tissue. The identities and locations of target substrates of FAP are poorly defined, in contrast to the related protease DPP4. This study is the first to characterize the physiological substrate repertoire of the DPP activity of endogenous FAP present in plasma. Four substrates, neuropeptide Y (NPY), peptide YY, B-type natriuretic peptide and substance P, were analyzed by mass spectrometry following proteolysis in human or mouse plasma, and by in vivo localization in human liver tissues with cirrhosis and hepatocellular carcinoma (HCC). NPY was the most efficiently cleaved substrate of both human and mouse FAP, whereas all four peptides were efficiently cleaved by endogenous DPP4, indicating that the in vivo degradomes of FAP and DPP4 differ. All detectable DPP-specific proteolysis and C-terminal processing of these neuropeptides was attributable to FAP and DPP4, and plasma kallikrein, respectively, highlighting their combined physiological significance in the regulation of these neuropeptides. In cirrhotic liver and HCC, NPY and its receptor Y2R, but not Y5R, were increased in hepatocytes near the parenchymal-stromal interface where there is an opportunity to interact with FAP expressed on nearby activated mesenchymal cells in the stroma. These novel findings provide insights into the substrate specificity of FAP, which differs greatly from DPP4, and reveal a potential function for FAP in neuropeptide regulation within liver and cancer biology.
Collapse
Affiliation(s)
- Pok Fai Wong
- Centenary Institute of Cancer Medicine and Cell Biology, Sydney Medical School, The University of Sydney, NSW 2006, Australia
| | - Margaret G Gall
- Centenary Institute of Cancer Medicine and Cell Biology, Sydney Medical School, The University of Sydney, NSW 2006, Australia
| | - William W Bachovchin
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111, USA
| | - Geoffrey W McCaughan
- Centenary Institute of Cancer Medicine and Cell Biology, Sydney Medical School, The University of Sydney, NSW 2006, Australia
| | - Fiona M Keane
- Centenary Institute of Cancer Medicine and Cell Biology, Sydney Medical School, The University of Sydney, NSW 2006, Australia
| | - Mark D Gorrell
- Centenary Institute of Cancer Medicine and Cell Biology, Sydney Medical School, The University of Sydney, NSW 2006, Australia.
| |
Collapse
|
15
|
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem J 2015; 473:605-14. [PMID: 26635356 PMCID: PMC4764976 DOI: 10.1042/bj20151085] [Citation(s) in RCA: 90] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Accepted: 12/03/2015] [Indexed: 01/08/2023]
Abstract
Fibroblast growth factor 21 (FGF21), a hormone implicated in the regulation of glucose homoeostasis, insulin sensitivity, lipid metabolism and body weight, is considered to be a promising therapeutic target for the treatment of metabolic disorders. Despite observations that FGF21 is rapidly proteolysed in circulation rending it potentially inactive, little is known regarding mechanisms by which FGF21 protein levels are regulated. We systematically investigated human FGF21 protein processing using mass spectrometry. In agreement with previous reports, circulating human FGF21 was found to be cleaved primarily after three proline residues at positions 2, 4 and 171. The extent of FGF21 processing was quantified in a small cohort of healthy human volunteers. Relative abundance of FGF21 proteins cleaved after Pro-2, Pro-4 and Pro-171 ranged from 16 to 30%, 10 to 25% and 10 to 34%, respectively. Dipeptidyl peptidase IV (DPP-IV) was found to be the primary protease responsible for N-terminal cleavages after residues Pro-2 and Pro-4. Importantly, fibroblast activation protein (FAP) was implicated as the protease responsible for C-terminal cleavage after Pro-171, rendering the protein inactive. The requirement of FAP for FGF21 proteolysis at the C-terminus was independently demonstrated by in vitro digestion, immunodepletion of FAP in human plasma, administration of an FAP-specific inhibitor and by human FGF21 protein processing patterns in FAP knockout mouse plasma. The discovery that FAP is responsible for FGF21 inactivation extends the FGF21 signalling pathway and may enable novel approaches to augment FGF21 actions for therapeutic applications.
Collapse
|
16
|
Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015; 108:466-72. [PMID: 25836944 DOI: 10.1016/j.diabres.2015.02.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 01/28/2015] [Accepted: 02/20/2015] [Indexed: 02/07/2023]
Abstract
UNLABELLED Non-alcoholic fatty liver disease (NAFLD) is common in diabetes and obesity but few have clinically significant liver fibrosis. Improved risk-assessment is needed as the commonly used clinical-risk algorithm, the NAFLD fibrosis score (NFS), is often inconclusive. AIMS To determine whether circulating fibroblast activation protein (cFAP), which is elevated in cirrhosis, has value in excluding significant fibrosis, particularly combined with NFS. METHODS cFAP was measured in 106 with type 2 diabetes who had transient elastography (Cohort 1) and 146 with morbid obesity who had liver biopsy (Cohort 2). RESULTS In Cohort 1, cFAP (per SD) independently associated with median liver stiffness (LSM) ≥ 10.3 kPa with OR of 2.0 (95% CI 1.2-3.4), p=0.006. There was 0.12 OR (95% CI 0.03-0.61) of LSM ≥ 10.3 kPa for those in the lowest compared with the highest FAP tertile (p=0.010). FAP levels below 730 pmol AMC/min/mL had 95% NPV for LSM ≥ 10.3 kPa and reclassified 41% of 64 subjects from NFS 'indeterminate-risk' to 'low-risk'. In Cohort 2, cFAP (per SD), associated with 1.7 fold (95% CI 1.1-2.8) increased odds of significant fibrosis (F ≥ 2), p=0.021, and low cFAP reclassified 49% of 73 subjects from 'indeterminate-risk' to 'low-risk'. CONCLUSIONS Lower cFAP, when combined with NFS, may have clinical utility in excluding significant fibrosis in diabetes and obesity.
Collapse
Affiliation(s)
- K H Williams
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; The Charles Perkins Centre, Building D17, Johns Hopkins Drive, The University of Sydney, NSW, Australia; NHMRC Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.
| | - A J Viera de Ribeiro
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| | - E Prakoso
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| | - A S Veillard
- NHMRC Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.
| | - N A Shackel
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| | - Y Bu
- Inflammation and Infection Research Centre, School of Medical Sciences, Wallace Wurth Building, University of New South Wales, Sydney, NSW 2052, Australia.
| | - B Brooks
- Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; Sydney Nursing School, Building M02, The University of Sydney, NSW 2006, Australia.
| | - E Cavanagh
- Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia.
| | - J Raleigh
- Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia.
| | - S V McLennan
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; The Charles Perkins Centre, Building D17, Johns Hopkins Drive, The University of Sydney, NSW, Australia.
| | - G W McCaughan
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| | - W W Bachovchin
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
| | - F M Keane
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| | - A Zekry
- Inflammation and Infection Research Centre, School of Medical Sciences, Wallace Wurth Building, University of New South Wales, Sydney, NSW 2052, Australia; The St George Hospital, Gray Street, Kogarah, NSW 2217, Australia.
| | - S M Twigg
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, Australia; The Charles Perkins Centre, Building D17, Johns Hopkins Drive, The University of Sydney, NSW, Australia.
| | - M D Gorrell
- Sydney Medical School, The Edward Ford Building (A27), The University of Sydney, NSW, Australia; Centenary Institute, Locked Bag 6, Newtown, NSW 2042, Australia.
| |
Collapse
|
17
|
Zhang H, Chen Y, Wadham C, McCaughan GW, Keane FM, Gorrell MD. Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal adhesion kinase and paxillin. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2014; 1853:470-80. [PMID: 25486458 DOI: 10.1016/j.bbamcr.2014.11.029] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 11/24/2014] [Accepted: 11/26/2014] [Indexed: 12/12/2022]
Abstract
Dipeptidyl peptidase 9 (DPP9) is a ubiquitously expressed member of the DPP4 gene and protease family. Deciphering the biological functions of DPP9 and its roles in pathogenesis has implicated DPP9 in tumor biology, the immune response, apoptosis, intracellular epidermal growth factor-dependent signaling and cell adhesion and migration. We investigated the intracellular distribution of DPP9 chimeric fluorescent proteins and consequent functions of DPP9. We showed that while some DPP9 is associated with mitochondria, the strongest co-localization was with microtubules. Under steady state conditions, DPP9 was not seen at the plasma membrane, but upon stimulation with either phorbol 12-myristate 13-acetate or epidermal growth factor, some DPP9 re-distributed towards the ruffling membrane. DPP9 was seen at the leading edge of the migrating cell and co-localized with the focal adhesion proteins, integrin-β1 and talin. DPP9 gene silencing and treatment with a DPP8/DPP9 specific inhibitor both reduced cell adhesion and migration. Expression of integrin-β1 and talin was decreased in DPP9-deficient and DPP9-enzyme-inactive cells. There was a concomitant decrease in the phosphorylation of focal adhesion kinase and paxillin, indicating that DPP9 knockdown or enzyme inhibition suppressed the associated adhesion signaling pathway, causing impaired cell movement. These novel findings provide mechanistic insights into the regulatory role of DPP9 in cell movement, and may thus implicate DPP9 in tissue and tumor growth and metastasis.
Collapse
Affiliation(s)
- Hui Zhang
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Yiqian Chen
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Carol Wadham
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Geoffrey W McCaughan
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Fiona M Keane
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Mark D Gorrell
- Centenary Institute and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
| |
Collapse
|
18
|
Keane FM, Yao TW, Seelk S, Gall MG, Chowdhury S, Poplawski SE, Lai JH, Li Y, Wu W, Farrell P, Vieira de Ribeiro AJ, Osborne B, Yu DMT, Seth D, Rahman K, Haber P, Topaloglu AK, Wang C, Thomson S, Hennessy A, Prins J, Twigg SM, McLennan SV, McCaughan GW, Bachovchin WW, Gorrell MD. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 2013; 4:43-54. [PMID: 24371721 PMCID: PMC3871272 DOI: 10.1016/j.fob.2013.12.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 12/04/2013] [Accepted: 12/04/2013] [Indexed: 02/08/2023] Open
Abstract
The protease fibroblast activation protein (FAP) is a specific marker of activated mesenchymal cells in tumour stroma and fibrotic liver. A specific, reliable FAP enzyme assay has been lacking. FAP's unique and restricted cleavage of the post proline bond was exploited to generate a new specific substrate to quantify FAP enzyme activity. This sensitive assay detected no FAP activity in any tissue or fluid of FAP gene knockout mice, thus confirming assay specificity. Circulating FAP activity was ∼20- and 1.3-fold less in baboon than in mouse and human plasma, respectively. Serum and plasma contained comparable FAP activity. In mice, the highest levels of FAP activity were in uterus, pancreas, submaxillary gland and skin, whereas the lowest levels were in brain, prostate, leukocytes and testis. Baboon organs high in FAP activity included skin, epididymis, bladder, colon, adipose tissue, nerve and tongue. FAP activity was greatly elevated in tumours and associated lymph nodes and in fungal-infected skin of unhealthy baboons. FAP activity was 14- to 18-fold greater in cirrhotic than in non-diseased human liver, and circulating FAP activity was almost doubled in alcoholic cirrhosis. Parallel DPP4 measurements concorded with the literature, except for the novel finding of high DPP4 activity in bile. The new FAP enzyme assay is the first to be thoroughly characterised and shows that FAP activity is measurable in most organs and at high levels in some. This new assay is a robust tool for specific quantitation of FAP enzyme activity in both preclinical and clinical samples, particularly liver fibrosis. A novel synthetic fluorogenic substrate is proven to be FAP-specific. Mice have higher levels of circulating FAP activity compared to baboons or humans. No FAP activity was detected in urine or bile but bile contained high DPP4 activity. FAP activity is greatest in pancreas, uterus, salivary gland, skin and lymph node. FAP activity and protein is elevated in both serum and liver in human liver disease.
Collapse
Key Words
- ALD, alcoholic liver disease
- AMC, amino-4-methylcoumarin
- Biomarker
- DMSO, dimethyl sulfoxide
- DPP4, dipeptidyl peptidase 4
- Dipeptidyl peptidase
- EDTA, ethylene diamine tetra acetic acid
- FAP, fibroblast activation protein-α
- Fibroblast
- Fibrosis
- HCV, hepatitis C virus
- LDS, lithium dodecyl sulphate
- LN, lymph node
- Liver disease
- ND, non-diseased
- PBC, primary biliary cirrhosis
- PBMC, peripheral blood mononuclear cells
- PBS, phosphate-buffered saline
- PEP, prolyl endopeptidase
- PVDF, polyvinylidene fluoride
- Protease activity
- Protease substrates
- STLV, simian T-cell lymphotrophic virus
- gko, gene knock out
- het, heterozygous
- mAb, monoclonal antibody
- wt, wild type
- yrs, years
Collapse
Affiliation(s)
- Fiona M Keane
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Tsun-Wen Yao
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | | | - Margaret G Gall
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Sumaiya Chowdhury
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Sarah E Poplawski
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Jack H Lai
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Youhua Li
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Wengen Wu
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Penny Farrell
- Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Ana Julia Vieira de Ribeiro
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Brenna Osborne
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Denise M T Yu
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - Devanshi Seth
- Centenary Institute, Camperdown, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Khairunnessa Rahman
- Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Paul Haber
- Sydney Medical School, University of Sydney, NSW, Australia ; Drug Health Services, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - A Kemal Topaloglu
- Pediatric Endocrinology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - Chuanmin Wang
- Sydney Medical School, University of Sydney, NSW, Australia ; Collaborative Transplantation Research Group, Bosch Institute, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Sally Thomson
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Annemarie Hennessy
- Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia ; School of Medicine, University of Western Sydney, NSW, Australia
| | - John Prins
- Mater Medical Research Institute, University of Queensland, and Department of Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Stephen M Twigg
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Susan V McLennan
- Sydney Medical School, University of Sydney, NSW, Australia ; Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Geoffrey W McCaughan
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| | - William W Bachovchin
- Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Mark D Gorrell
- Centenary Institute, Camperdown, NSW, Australia ; Sydney Medical School, University of Sydney, NSW, Australia
| |
Collapse
|